Barriers to the use of three-month paliperidone palmitate formulation: a study from an Italian real-world setting.
Giovanna CirnigliaroVera BattiniRita CafaroGiulia MosiniSimone VanzettoTiziano ProdiMonica MacellaroRodolfo LeuzziDario ContiCarla CarnovaleBernardo Dell'ossoPublished in: Expert review of neurotherapeutics (2023)
PP3M initiation was associated with an overall HRU reduction. Subjects switched to PP3M had similar HRU when compared with those who did not, suggesting similar clinical conditions in both groups.
Keyphrases